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ABSTRACT
Aims To investigate whether smokers prescribed varenicline had lower risks of serious ill-health during the 4 years
following treatment compared with those prescribed nicotine replacement therapy (NRT).Design Observational cohort
study of electronic medical records. Setting A total of 370 UK general practices sampled from the Clinical Practice
Research Datalink. Participants A total of 126718 patients aged 18 and over who were issued smoking cessation
prescriptions between 1 September 2006 and 31 March 2014. Measurements Our primary outcome was all-cause
mortality within 2 years of ﬁrst prescription as indicated by linked Ofﬁce of National Statistics data. Our secondary
outcomes were cause-speciﬁc mortality, all-cause, cause-speciﬁc hospitalization, primary care diagnosis of myocardial
infarction or chronic obstructive pulmonary disease (COPD), body mass index and attendance rate to primary care within
2 years of ﬁrst prescription. Risk differences and 95% conﬁdence intervals were estimated bymultivariable adjusted regres-
sion and propensity score matched regression. We used instrumental variable analysis to overcome residual confounding.
Findings People prescribed vareniclinewere healthier at baseline than those prescribed NRT in almost all characteristics,
highlighting the potential for residual confounding. Our instrumental variable analysis results found that people prescribed
varenicline had a similar risk of mortality at 2 years [risk difference per 100 patients treated = 0.67, 95% conﬁdence
interval (CI) = -0.11 to 1.46)] to those prescribed NRT, and there were similar rates of all-cause hospitalization, incident
primary-care diagnoses of myocardial infarction and COPD. People prescribed varenicline subsequently attended primary
care less frequently.Conclusions Smokers prescribed varenicline in primarycare in the United Kingdomdo not appear to
be less likely to die, be hospitalized or experience a myocardial infarction or chronic obstructive pulmonary disease during
the following 2 years compared with smokers prescribed nicotine replacement therapy, but they gain more weight and
attend primary care less frequently.
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INTRODUCTION
Meta-analyses of randomized controlled trials (RCTs) have
shown that ﬁve additional smokers will quit for every
100 smokers allocated to varenicline rather than nicotine
replacement therapy (NRT) [1]. These meta-analyses have
also shown that patients allocated to varenicline are un-
likely to be at increased risk of short-term neuropsychiatric
or cardiovascular adverse events [2,3]. Both randomized
trials and observational studies have suggested that pa-
tients prescribed varenicline are less likely to smoke in the
short term [4,5]. These reductions in smoking should
translate into health beneﬁts in the years following treat-
ment. However, we have relatively little evidence about
the effects of prescribing varenicline in primary care on
health outcomes in the years following treatment.
Experimental evidence about the effects of prescribing
varenicline on health more than a year after prescription
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is limited, because trials of smoking cessation medications
rarely have follow-up greater than a year. Furthermore,
the number of participants in clinical trials is relatively
low and trial participants are unlikely to be representative
of patients in primary care. In addition, adherence to treat-
ment regimens in RCTsmay not be comparable to everyday
clinical care, and there may be selective outcome reporting
of trials. Hence, trials provide relatively little evidence about
the longer-term effects of smoking cessation therapy on
outcomes that are perhaps most important to smokers
and clinicians, such as mortality, hospitalization and
attendance to primary care. A recent observational study
investigated the association of smoking cessation medica-
tions and cardiovascular and neuropsychiatric adverse
events. However, it had a limited follow-up of 6 months,
did not investigate important outcomes such as mortality
and hospitalization and suffered potentially from residual
confounding [6].
Residual confounding is a major issue, because patients
prescribed varenicline tend to be healthier than those
prescribed NRT [7]. Traditional epidemiological methods
attempt to account for these differences by adjusting for
or matching on observed differences using multivariable
adjusted regression or propensity scores. These methods
depend upon the assumption that there are no unmea-
sured differences between those prescribed varenicline
and NRT. This assumption is implausible. There are many
differences between patients that are difﬁcult or impossible
tomeasure in databases of electronicmedical records, such
as socio-economic position, genetics and strength of addic-
tion. An alternative approach is instrumental variable
analysis, which exploits different assumptions [8]. An in-
strumental variable is a naturally occurring variation in
the data set that can be used as a proxy for intervention
the patient received. Instruments are deﬁned by three as-
sumptions. First, the instrument must be associated with
the likelihood of receiving an intervention. Secondly, the
association of the instrument and the outcome must not
be confounded. Thirdly, the instrument must only affect
the outcome through its effect on the likelihood of receiv-
ing the intervention. Physicians’ preferences for one medi-
cation over another are a potential instrument for the
medications they prescribe to their patients [9]. Physicians
who prefer varenicline are more likely to prescribe it.
Physicians’ preferences for varenicline may not relate to
their patients’ baseline comorbidities. Finally, physicians’
preferences should not affect their patients’ outcomes
directly, independent of the prescription they issue. If these
assumptions hold, then instrumental variable analysis
would provide unbiased estimates of the causal effect of
varenicline.
We have used these methods to provide evidence that
varenicline causes patients to be more likely to quit
smoking [5]. In the current study, we investigated if
smokers prescribed varenicline had lower risks of serious
ill-health compared to those prescribed NRT during the 4
years following treatment. We used three approaches to
control for potential confounding: multivariable adjusted
analyses, propensity score matched analyses and instru-
mental variable regression using data from the UKClinical
Practice Research Datalink (CPRD). Previous studies have
used data from UK electronic medical records to investigate
the effects of varenicline on neuropsychiatric outcomes [7].
We add to these results by investigating the effects of
smoking cessation therapy on mortality, outcomes in
primary and secondary care and the frequency of primary
care consultations.
METHODS
We conducted a prospective cohort study of all people
prescribed varenicline or NRT in a sample of primary care
practices in the United Kingdom. All hypotheses and
analyses were pre-speciﬁed and a study protocol was
published [10]. The CPRD’s terms and conditions for
accessing the data do not allow us to disseminate individ-
ual level patient data. However, researchers interested in
accessing the data should contact the CPRD directly
(enquires@cprd.com). The statistical code used to produce
these results can be accessed online (https://github.com/
nmdavies/varenicline-safety/). The study is registered at
clinicaltrials.gov (NCT: NCT02681848) and the Open
Science Framework (https://osf.io/g9ch2/).
Study design and participants
The CPRD contains records from more than 15 million
people, who are representative of the population of the
United Kingdom [11]. More than 98% of the UK popula-
tion are registered with a general practitioner (GP). GPs
provide access to National Health Service (NHS) services,
and patients are limited to a choice of GP practice within
their geographical area. Data on mortality and hospital ad-
mission from the UK Ofﬁce of National Statistics and the
Hospital Episodes Statistics data sets have been linked to
all the practices included in this analysis. People who
attended linked practices are similar to those from unlinked
practices [7]. We restricted our analysis to people with
‘acceptable’ records at practices which were designated as
‘up-to-standard’ by the CPRD [11]. Acceptable records
were those with information on the date of birth and sex,
ﬁrst registration date and no breaks in their registration.
Up-to-standard practices provided continuous reporting of
data and reported when their patients registered at and left
the practice. We sampled all those prescribed NRT or
varenicline by a GP at a linked practice after 1 September
2006 (when varenicline was introduced to the United
Kingdom) until the end of follow-up in the linked data on
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31March 2014.We included people whowere issued their
ﬁrst prescription of either varenicline or NRT within the
study period. To ensure that patients were starting a new
course of treatment, and there had been sufﬁcient registra-
tion period to deﬁne covariates, we excluded prescriptions
issued to people who were prescribed smoking cessation
medications in the 18 months prior to the start of study
follow-up. To ensure sufﬁcient medical history to deﬁne
covariates, we excluded prescriptions issued to people
who registered at a practice within the previous year. We
excluded people prescribed both NRT and varenicline on
the same day. Supporting information, Fig. SA provides a
ﬂow-chart of study inclusions and exclusions.
Exposures
Exposure was the ﬁrst prescription of either varenicline or
NRT. Therefore, allocation to treatment remained the same
throughout the entire follow-up period regardless of
subsequent prescriptions. We did this for two reasons:
ﬁrst, to ensure that our analysis was comparable to an
intention-to-treat analysis in a randomized controlled trial
[12,13]; and secondly, because treatment-switchingwill be
related strongly to the characteristics of participants, so
that analyses which model treatment-switching are likely
to suffer from residual confounding. We estimated the
effect of initially prescribing varenicline compared to
initially prescribing NRT. We did not investigate another
smoking cessation agent, bupropion, because it is rarely
prescribed in the United Kingdom, and large randomized
trials and systematic reviews have demonstrated that it is
less efﬁcacious than varenicline [4,14].
Outcomes
Our primary outcome was all-cause mortality 2 years after
the ﬁrst prescription. In the Supporting information, we
report differences in all outcomes at 3, 6, 9, 12 and
48 months. We chose the primary outcome and timing a
priori because previous observational studies have sug-
gested that differences in mortality occur within 2 years
of smoking cessation [15]. We also investigated the follow-
ing secondary outcomes: mortality due to chronic lung
disease (ICD-10 codes = J40–44), lung cancer (ICD-10
codes = C34), coronary heart disease (ICD-10
codes = I21–25), pneumonia (ICD-10 = J12–18), cerebro-
vascular disease (ICD-10 = I60–69), diabetes (ICD-
10 = E10–14), external causes (ICD-10 = V01-Y98);
all-cause in-patient hospitalization; in-patient hospitaliza-
tion for the same causes asmortality above (using the same
ICD-10 codes as for mortality); incident diagnosis of myo-
cardial infarction, chronic obstructive pulmonary disease
or diabetes (Read code lists available in the Supporting in-
formation); frequency of primary care consultations; and
weight. The Read code lists were based on previously
validated code lists [16].
Potential confounders
We included the following potential confounders at
baseline: sex; age; body mass index (BMI kg/m2); alcohol
drugmisuse, deﬁned using Read codes; socio-economic po-
sition measured by the index of multiple deprivation (IMD);
an indicator for having more than ﬁve primary care
consultations in the year before ﬁrst prescription;
indicators for year of prescription; any previous prescrip-
tions of hypnotics; antipsychotics; antidepressants; diagno-
ses of: self-harm;myocardial infarction; chronic obstructive
pulmonary disease; any psychiatric disease; or serious
comorbidities (Charlson Index) or any psychiatric disease.
Product and Read codes lists for all potential confounders
are available in the Supporting information. A total of
13.6% of patientsweremissing data on BMI and0.1%were
missing data on socio-economic position.We imputed these
values using the Imputation by Chained Equations (ICE)
package in Stata; see Supporting information, Table S1 for
comparison of imputed and complete samples [17].
Data analysis
Weused Stata version 14MP for all analyses. The statistical
code used to produce these results can be accessed online
(https://github.com/nmdavies/varenicline-safety/).
Multivariable adjusted analysis
We used logistic regression to estimate the associations of
smoking cessation medications and the outcomes and re-
port odds ratios (OR) and 95% conﬁdence intervals (CI).
We did not use Cox survival models as the proportional
hazards assumption did not hold (based on the phtest com-
mand in Stata). Basic adjusted results account for sex, year
of ﬁrst prescription and age. The fully adjusted results also
account for all potential confounders described above.
Propensity score analysis
We created a propensity score using the command
psmatch2 and the covariates described above [18]. For this
analysis, we replaced missing values of BMI and IMD at the
mean and included indicator variables for missing values.
We matched each patient prescribed varenicline with a
patient with a similar propensity score using one-to-one
nearest-neighbour matching with no caliper. All patients
prescribed varenicline had values of the propensity score
within the range of propensity scores for the patients pre-
scribed NRT. We estimated the ORs of outcomes within
each follow-up period and included the propensity score
as a covariate. The propensity score results were consistent
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with and depend upon similar assumptions (conditional
exchangeability) to the multivariable adjusted regression.
Therefore, we present the propensity score analyses in the
Supporting information.
Instrumental variable analysis
To address residual confounding by unobserved comorbid-
ities or other unmeasured confounders [7], we used instru-
mental variable analysis, which can provide unbiased
estimates of the effects of treatment in the presence of
unmeasured confounding [8,19]. Physicians’ prescribing
preferences for speciﬁc medications have been proposed
as potential instrumental variables for their prescriptions
[9]. Because the physicians’ preferences were not mea-
sured directly, we used the number of varenicline prescrip-
tions they issued to their previous seven patients as a proxy.
We pre-speciﬁed seven prior prescriptions in our protocol
on the basis of our previous study [20]. Physicians who
prescribed varenicline to their previous seven patients were
classiﬁed as preferring varenicline and physicians who pre-
scribed NRT to their previous seven patients were classiﬁed
as preferring NRT.
For each of the outcomes, we created a set of binary
outcomes indicating whether a patient had an event
within 3, 6, 9, 12, 24 and 48months of their ﬁrst prescrip-
tion. For each outcome, we censored patients who had an
inadequate follow-up.We used two-stage least-squares and
additive structural mean models, which estimate mean
and risk differences for continuous and binary outcomes,
respectively [21]. We tested the ﬁrst instrumental variable
assumption (instrument must be associated with the likeli-
hood of receiving an intervention) using a partial F-statistic
to estimate the association of the physicians’ previous pre-
scriptions (the instrument) and the prescription issued to
their current patient (the exposure).
We tested the second instrumental variable assumption
(whether the actual prescriptions and the instrumental
variable were associated with observed covariates) using
bias component plots (see Appendix for details) [22,23].
We restricted the instrumental variable analysis to physi-
cians who issued more than 10 smoking cessation therapy
prescriptions in our data set. This ensures that we had
sufﬁcient data to for each GPs. All standard errors and con-
ﬁdence intervals account for clustering of patients by GPs.
Patient involvement
We presented our plans for the research and subsequently
our results to the UKCentre for Alcohol and Tobacco Stud-
ies Smokers’ panel who provided feedback and recommen-
dations on the research; for example, the need for more
precise instrumental variable estimates of the effect on
the primary outcome.
RESULTS
Cohort characteristics
There were 126718 patients who attended one of 370
practices who met the study inclusion criteria (Supporting
information, Fig. S1). Of the included patients, 84976
(67.1%) were prescribed NRT and 41742 (32.9%) were
prescribed varenicline (Table 1). The type of NRT issued
to patients is shown in Supporting information, Table S2.
Of the patients initially prescribed varenicline, 73%were is-
sued more than one prescription for varenicline during the
following 3 months. Twenty per cent of patients initially
prescribed varenicline were issued more than 151 tablets
during the following 3 months, the minimum number of
tablets needed to adhere to a full course of treatment. Com-
pared to people prescribed NRT, those prescribed
varenicline were more likely to: be male, healthier, youn-
ger; andwere less likely to:misuse alcohol or drugs, be from
afﬂuent areas, be less frequent primary care attendees, to
have been prescribed hypnotics/anxiolytics, antipsychotics,
antidepressants, statins, antihypertensives or diabetic med-
ications and to have been diagnosed with self-harm, myo-
cardial infarction, chronic obstructive pulmonary disease,
any psychiatric disease or other chronic disease (Charlson
Index) (Table 1 and Supporting information, Fig. S2).
Tests of plausibility of the instrumental variable
assumptions
Physicians who prescribed varenicline to their previous pa-
tient were 24.5% (95% CI = 23.3 to 25.9%) more likely to
prescribe varenicline to their subsequent patients. The
instrument was the number of varenicline prescriptions
issued by each patient’s physician in their previous seven
ﬁrst-time smoking cessation scripts. This explained a
substantial proportion of the variation in prescribing: the
partial F-statistic, a measure of instrument strength,
ranged from 4045 to 7775 [24]. These parameters indi-
cate a strong instrument. The actual varenicline and
NRT prescriptions were associated more strongly with the
potential confounders than the instruments for these pre-
scriptions. The bias component plots suggested that after
accounting for the strength of the instrument, the bias
components for the instrumental variable were smaller
than those for the actual prescription for all covariates ex-
cept BMI, number of prior GP visits and deprivation
(Supporting information, Fig. S2 and Table S3).
Difference in mortality and morbidity at 2-year follow-up
Prescribing varenicline rather than NRT did not improve
outcomes during the 2 years following ﬁrst prescription
(Fig. 1). Speciﬁcally, varenicline increased the primary
outcome, all-cause mortality, relative to NRT, by 0.67
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additional deaths (95% CI = –0.11 to 1.46%) per 100
people treated. There was little detectable difference in
the effects of varenicline and NRTon cause-speciﬁc mortal-
ity, all-cause and cause-speciﬁc hospitalization and rates of
incident primary care diagnoses of myocardial infarction
and chronic obstructive pulmonary disease.
The effects of varenicline versus NRT during 4-year
follow-up
The instrumental variable results found that varenicline,
in comparison with NRT, was not associated with all-
cause or cause-speciﬁc or mortality at any point
throughout the 4-year follow-up (solid blue lines in
Fig. 2a). In contrast, the multivariable adjusted regres-
sion results found that patients prescribed varenicline
had lower all-cause and cause-speciﬁc mortality than
those prescribed NRT (solid and dashed red lines in Fig. 2
for basic and fully adjusted analyses, respectively). These
differences increased over time up to 4 years after the
initial prescription.
The instrumental variable results found that prescrib-
ing varenicline rather than NRT reduced all-cause in-
patient hospital admissions during the 9 months follow-
ing the initial prescription (solid blue lines, Fig. 3a).
However, by 4 years of follow-up this effect had reversed.
There was little evidence from the instrumental variable
analysis that varenicline reduced rates of cause-speciﬁc
hospital admission compared to NRT (solid blue lines,
Fig. 3b–f). In contrast, the multivariable results suggested
that patients prescribed varenicline were substantially
less likely to be hospitalized throughout the entire
follow-up (red lines in Fig. 3a). These differences attenu-
ated after adjustment for observed confounders. The mul-
tivariable adjusted analysis suggested that patients
prescribed varenicline rather than NRT generally had
lower cause-speciﬁc hospital admission for all outcomes
except lung cancer (red lines Fig. 3b–f).
Patients prescribed varenicline versus NRT gained
1.14 kg (95% CI = 0.08 to 2.20%) (Fig. 4a). This result
was consistent across all analytical methods. Patients
prescribed varenicline were also 19.5% (95% CI = 11.1
to 27.1%) less likely to attend primary care than those
prescribed NRT (Fig. 4b). After 4 years the instrumental
variable results found that patients prescribed varenicline
had a higher risk of diabetes-related mortality, but not
hospitalization (blue lines, Fig. 5a,b). This effect on dia-
betes may be related to weight gain [25]. There was lit-
tle evidence that varenicline lowered the risk of incident
primary care diagnoses of myocardial infarction or
Table 1 Baseline characteristics of patients prescribed varenicline or nicotine replacement therapy. Data are number (%) of patients unless
otherwise speciﬁed.
Nicotine replacement therapy
(n = 84976)
Varenicline
(n = 41742)
Male 39285 46.2% 20928 50.1%
Median age (SD) 46 24 44 19
Body mass index (SD) 25.5 7.1 25.7 6.6
Misuses alcohol 6199 7.3% 2086 5.0%
Misuses drugs 2484 2.9% 747 1.8%
Least deprived ﬁfth of patients 11209 13.2% 6427 15.4%
Most deprived ﬁfth of patients 20896 24.6% 9177 22.0%
Median number of primary care visits in prior year (SD) 6 8 5 6
Prescribed before 2009 38568 45.4% 10422 25.0%
Previous prescription of
hypnotics/anxiolytic 17419 20.5% 7114 17.0%
antipsychotic 16918 19.9% 5975 14.3%
antidepressant 42450 50.0% 17895 42.9%
statins 16534 19.5% 6217 14.9%
antihypertensive 17608 20.7% 6974 16.7%
diabetic medication 7798 9.2% 2710 6.5%
Previous diagnosis of
self-harm 8846 10.4% 3614 8.7%
myocardial infarction 2624 3.1% 708 1.7%
chronic obstructive pulmonary disease 6837 8.0% 2516 6.0%
chronic disease (Charlson Index) 32517 38.3% 13277 31.8%
any psychiatric disease 41275 48.6% 17005 40.7%
Follow-up time (years) 4.56 2.07 3.72 1.84
SD = standard deviation.
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chronic obstructive pulmonary disease (blue lines,
Fig. 5c,d).
Propensity score matched regression results are
available in the appendix (Supporting information,
Tables S4, S5). The propensity score results were similar
to the multivariable adjusted results. The distributions of
the propensity scores and the balance of covariates before
and after matching can be seen in Supporting information,
Figs S3, S4 and Table S6.
DISCUSSION
We found little evidence that patients prescribed
varenicline versus NRT had a lower risk of mortality, hos-
pitalization or primary care diagnosis of myocardial in-
farction or chronic obstructive pulmonary disease 2
years after ﬁrst prescription. Both multivariable adjusted
and instrumental variable regression suggested that pa-
tients prescribed varenicline attended primary care less
frequently during the 2 years following the ﬁrst
prescription.
Patients prescribed varenicline were healthier than
those prescribed NRT at baseline in almost all ways we
could measure. It is, therefore, likely that there are
differences in terms of unobserved characteristics (i.e. ge-
netics, income, education, strength of addiction and mo-
tivation to quit). Hence, the results from multivariable
adjusted and propensity score matched regression are un-
likely to reﬂect the causal effect of prescribing varenicline,
as both approaches depend upon the assumption that
there are no unmeasured confounders. This may explain
why we found implausibly large short-term differences in
all-cause and cause-speciﬁc mortality in the multivariable
adjusted and propensity score regression. In contrast, the
instrumental variable analysis suggested little short-term
effect of prescribing varenicline versus NRT on mortality;
these results are more robust to confounding by unob-
served patient characteristics (healthy user bias). We
found consistent evidence from all approaches that pa-
tients prescribed varenicline subsequently experienced in-
creases in weight and attended primary care less
frequently. This may suggest that varenicline affects
weight and GP attendance, potentially via its effects on
smoking cessation. In contrast, the other outcomes we
investigated may not be affected as strongly by
varenicline (and smoking cessation) as implied by the
partially or fully or multivariable adjusted differences. It
is conceivable that a similar bias afﬂicts results from
Figure 1 Instrumental variable estimates of the effects of prescribing varenicline versus nicotine replacement therapy on mortality and morbidity
during the 2 years following ﬁrst prescription. Conﬁdence intervals allow for clustering between physicians. Instrumental variable results use seven prior
prescriptions, and adjust for year of ﬁrst prescription, gender and age
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other observational studies of the effect of smoking
cessation [1].
Strengths and limitations
A key strength of our study is that we used three different
statistical techniques to address residual confounding,
multivariable adjusted, propensity score and instrumental
variable regression. Our multivariable adjusted results
could suffer from residual confounding and healthy user
bias. During this period there were safety warnings and
scientiﬁc papers which suggested that patients prescribed
varenicline might be at increased risk of neuropsychiatric
and cardiovascular adverse events. This could explain
why patients prescribed varenicline were healthier at
baseline. To overcome this, we used three different
approaches to control for differences between patients that
depend upon distinct assumptions. While themultivariable
adjusted association with mortality was large and
attenuated only modestly after adjustment for observed
confounders, the instrumental variable results suggested
little short-term reduction in mortality. Therefore, the asso-
ciation of varenicline prescriptions and mortality observed
in the multivariable and propensity score regression
analyses is likely to be due to residual confounding. The in-
strumental variable results could suffer from bias if there
are unobserved confounders affecting the instrument, the
physicians’ preferences and the outcome [22]. We investi-
gated this in terms of observed characteristics of the pa-
tients and found that the instruments tended to much
less associated with the observed confounders than the ac-
tual prescription the patient received. This is consistent
with the instrumental variable results being less biased.
Patients prescribed smoking cessation medication may
receive other cessation support (e.g. one-on-one or group
smoking cessation sessions). If patients prescribed
varenicline have a different likelihood of receiving these in-
terventions compared to those prescribed NRT, then it
could bias our observational results. The CPRD does not
contain detailed information on referrals to smoking cessa-
tion services. Treatment differences by prescription issued
would not necessarily bias our instrumental variable esti-
mates. However, if physicians who preferred varenicline
were also more likely to prescribe other interventions, this
could bias our instrumental variable results positively.
Only a proportion (73%) of patients prescribed
varenicline received more than one prescription in the 3-
month treatment period, and only 20% received sufﬁcient
tablets to complete a course of treatment. This means that
our results may underestimate the effects of complying
with treatment (as opposed to the effects of being
prescribed treatment). While the effect of prescribing
treatment is of more interest to clinicians, the effect of
complying is perhaps of most interest to patients. However,
Figure 2 The effect of prescribing varenicline on
(a) all-cause, (b) chronic lung disease-related (ICD
J40–44), (c) lung cancer (ICD C34), (d) coronary
heart disease (ICD I21–25), (e) pneumonia-related
(ICD J12–18) and (f) cerebrovascular disease (ICD
I60–69)-related mortality during the 4 years follow-
ing ﬁrst prescription as indicated via Ofﬁce of Na-
tional Statistics mortality records. Linear regression
is indicated by , solid line is adjusted for basic con-
founders, dashed line adjusts for all confounders
listed in Table 1 and the instrumental variable results
are indicated by ; 95% conﬁdence intervals indi-
cated. Conﬁdence intervals allow for clustering be-
tween physicians. The multivariable adjusted results
adjust for all the covariates listed in Table 1. Instru-
mental variable results use seven prior prescriptions.
[Colour ﬁgure can be viewed at wileyonlinelibrary.
com]
a b
c d
e f
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it is difﬁcult to estimate the effects of compliance, indepen-
dently of treatment initiation, because compliance is
non-random.
A strength of our study is that we published a protocol
and pre-speciﬁed our primary outcome [10]. A potential
limitation of our study is that we had no data on patients’
use of over-the-counter NRT. This means that patients
observed in our study may have attempted to quit
previously without attending primary care. However, as
varenicline is only available via prescription in the United
Kingdom, we are likely to have observed all uses of
varenicline. However, smokers who purchase over-the-
counter NRT are unlikely to be representative of patients
who attend primary care for smoking cessation advice.
Therefore, even if we had the data, users of over-the-
counter NRT are unlikely to be an appropriate control
group for patients prescribed varenicline. Furthermore,
our results relate to the initial decision to prescribe either
varenicline or NRT, which may not reﬂect the effects of
longer-term prescribing. Our results are therefore likely to
be representative of the treatment decisions and outcomes
of patients who consult with physicians about smoking
cessation.
Our outcomes were derived from validated code lists
and algorithms. However, it is possible that not all adverse
events are coded in the patients’ electronicmedical records.
While this is a concern for the primary care diagnoses,
there is unlikely to be missing information for hospital
a b
c d
e f
Figure 3 The effect of prescribing varenicline on
(a) all-cause, (b) chronic lung disease-related (ICD
J40–44), (c) lung cancer (ICD C34), (d) coronary
heart disease (ICD I21–25), (e) pneumonia-related
(ICD J12–18) and (f) cerebrovascular disease (ICD
I60–69)-related hospital in-patient admission during
the 4 years following ﬁrst prescription as indicated
via Ofﬁce of National Statistics death records. Linear
regression is indicated by , solid line is adjusted for
basic confounders, dashed line adjusts for all con-
founders listed in Table 1 and the instrumental vari-
able results are indicated by ; 95% conﬁdence
intervals indicated. Conﬁdence intervals allow for
clustering between physicians. The fully multivariable
adjusted results adjust for all the covariates listed in
Table 1. Instrumental variable results use seven prior
prescriptions. [Colour ﬁgure can be viewed at
wileyonlinelibrary.com]
a b
Figure 4 Effect of prescribing varenicline on (a) weight (kg) and (b) frequency of attendance to primary care during the 4 years following initial pre-
scription. Linear regression is indicated by , solid line is adjusted for basic confounders, dashed line adjusts for all confounders listed in Table 1 and the
instrumental variable results are indicated by ; 95% conﬁdence intervals indicated. [Colour ﬁgure can be viewed at wileyonlinelibrary.com]
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admissions or all-cause mortality. These data come from
linked national administrative records and validation stud-
ies have found that they record outcomes accurately [26].
A limitation of our study is that we only followed pa-
tients for up to 4 years. This means we were not able to test
whether prescribing varenicline affected long-term health
outcomes. Many of the adverse health conditions associ-
ated with tobacco consumption are the result of many
years of cumulative exposure to tobacco smoke (e.g. lung
cancer). Future studies could follow-up patients for longer
using routine health records and potentially use recently
proposed instrumental variable estimators for survival
analysis [27].
Comparison with other studies
Our instrumental variable results suggested that
varenicline was unlikely to have large effects on risk of
coronary heart disease mortality in the year following ﬁrst
prescription (risk difference (RD) per 100 patients
treated = 0.05%, 95% CI = –0.11 to 0.21%; hospitaliza-
tion due to coronary heart disease (RD = 0.34%, 95%
CI = 0.00 to 0.68%); or primary care diagnoses of myocar-
dial infarction (RD = 0.08%, 95% CI = –0.13 to 0.29%).
This means we can exclude a greater than 1 in 147
increase in risk of coronary heart disease mortality; this is
likely to be smaller than the longer-term reduction in risk
of cardiovascular events caused by quitting smoking. In
comparison, a network meta-analysis of randomized trials
found that participants allocated to varenicline had
similar rates of major adverse cardiovascular events
(RD = 0.06%, 95% CI = –0.14 to 0.17%, assuming 0.2
events per 100 allocated to NRT) [28]. The CATS trial
(Cardiac Assessments Following Different Treatments of
Smoking Cessation Medications in Subjects With and
Without Psychiatric Disorders), an extension to the
EAGLES study (Evaluating Adverse Events in a Global
Smoking Cessation Study), found that participants
allocated to varenicline had similar risk of major adverse
cardiovascular events to those allocated to NRT in the
6–12 months following treatment (RD = 0.15%, 95%
CI = –0.44 to 0.14%) [29]. However, the follow-up to this
study was relatively short. The multivariable adjusted
estimates of the effect of varenicline on rates of primary
care diagnosis of myocardial infarction were similar in
magnitude to a previous observational study using
electronic medical records [6].
Generalizability
The CPRD is representative of the United Kingdom, there-
fore our results are likely to reﬂect the association of
smoking cessation medications and adverse outcomes in
primary care in the United Kingdom. Consequently, the in-
dividuals in our study are likely to have more comorbidity
and be more representative of the general population than
participants of randomized controlled trials. Whereas only
seven (0.09%)of 8058 participants in the EAGLES trial died
within 24 weeks of randomization, 740 (0.72%) of
103162 patients in the CPRD died within 6months of ﬁrst
prescription. Our instrumental variable results estimate a
so-called ‘local average treatment effect’, under the
assumption of a monotonic effect of the instrument on
the likelihood of being prescribed varenicline [30]. This
assumption requires that a patient who is prescribed
varenicline by a physician who prefers NRT would also
receive varenicline had they attended a physician who pre-
ferred varenicline, and vice versa. This is the average effect
of varenicline in patients whose treatment was affected by
their physician’s preferences. These estimates may not be
Figure 5 Effect of prescribing varenicline on dia-
betes-related (ICD E10–14) (a) mortality and (b)
in-patient admission, primary-care diagnosis of (c)
myocardial infarction and (d) chronic obstructive
pulmonary disease during the 4 years following ini-
tial prescription. Linear regression is indicated by ,
solid line is adjusted for basic confounders, dashed
line adjusts for all confounders listed in Table 1 and
the instrumental variable results are indicated by
; 95% conﬁdence intervals indicated. Conﬁ-
dence intervals allow for clustering between physi-
cians. The fully multivariable adjusted results adjust
for all the covariates listed in Table 1. Instrumental
variable results use seven prior prescriptions.
[Colour ﬁgure can be viewed at
wileyonlinelibrary.com]
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valid for other patients; for example, patients who have
strong contraindications for varenicline.
Patients who were prescribed varenicline as part of
their everyday clinical care experienced similar rates of ad-
verse health outcomes to patients prescribed NRT during
the 4 years following treatment. Therewere few differences
in rates of all-cause and cause-speciﬁc mortality or hospi-
talization. However, consistent with previous studies [31],
patients prescribed varenicline gained more weight and
had a higher risk of diabetes. These results raise questions
about the effects of prescribing varenicline on health in
the years following treatment. Patients who quit smoking
may need additional health monitoring in the years follow-
ing cessation.
Study registration
NCT02681848.
Data access
The statistical code used to produce these results can be
accessed here: (https://github.com/nmdavies/varenicline-
safety/). The data set used in this study was extracted from
the CPRD, which can be accessed by contacting the CPRD
kc@cprd.com.
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Figure S1 Flow-chart of the number (n) of patients and
records assessed for eligibility and reasons for exclusion.
Figure S2 Relative linear regression and instrumental
variable bias component terms instrumental variable
results are indicated by and , respectively; 95% conﬁ-
dence intervals plotted. The patients’ actual prescriptions
were associated more strongly with the measured covari-
ates than the proposed instrument, even after taking into
account the instrument strength. This suggests that the
instrumental variable estimates are likely to be less biased
than the linear regression estimates.
Figure S3 Distributions of propensity scores by treatment
prescribed before matching.
Figure S4 Distributions of propensity scores by treatment
prescribed after matching.
Table S1 Distributions of imputed characteristics in the im-
putation data sets and in observed data (i.e. without
imputation) n eligible = 126718.
Table S2 Type of nicotine replacement therapy prescribed
to patients.
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Table S3 Estimated linear regression and instrumental var-
iable bias components.
Table S4 Adjusted relative outcome rate among patients
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Table S5 Adjusted relative outcome frequency among
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therapy using propensity score methods. Follow-up at 3,
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